A Phase III trial has demonstrated that zoliflodacin – a single-dose oral antibiotic – is highly effective against drug‐resistant gonorrhea, offering an innovative solution to a mounting public health threat. The encouraging results suggest a potential game‐changer in the fight against antibiotic-resistant infections.
#healthcare #pharmaceuticals #publichealth #drugdevelopment
Saturday, December 13, 2025, 8:21 pm / permalink 16937 / 2 stories in 2 months
Kathleen Medora / aacr - SAN ANTONIO – A mobile health (mHealth) intervention for adolescent and young adult breast cancer survivors that offered tailored support by monitoring electronic patient-reported outcomes (ePROs) significantly improved quality of life and symptoms relate…
Saturday, December 13, 2025, 9:21 am / permalink 16922 / 6 stories in 2 months
Kathleen Medora / aacr - SAN ANTONIO – Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the San …
Saturday, December 13, 2025, 9:21 am / permalink 16921 / 3 stories in 2 months
Kathleen Medora / aacr - Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 4:21 am / permalink 16917 / 6 stories in 2 months
go - King Charles III will speak about his cancer diagnosis and recovery during a TV broadcast on Friday as the monarch continues to use his personal story to encourage others to get the early screening that can boost their chances of survival
Saturday, December 13, 2025, 4:21 am / permalink 16916 / 4 stories in 2 months
fiercehealthcare - Dueling partisan proposals to address the expiry of the Affordable Care Act subsidies both failed to advance in the Senate on Thursday.
#healthcare #publichealth #governmentpolicy
Saturday, December 13, 2025, 3:21 am / permalink 16914 / 7 stories in 2 months
medicalxpress - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment af…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 1:21 am / permalink 16912 / 5 stories in 2 months
medicalxpress - Tanning bed use is tied to almost a three-fold increase in melanoma risk, and for the first time, scientists have shown how these devices cause melanoma-linked DNA damage across nearly the entire skin surface, reports a new study led by Northwestern Medic…
Saturday, December 13, 2025, 12:21 am / permalink 16910 / 2 stories in 2 months
Judge orders Leapfrog to remove safety grades for five Florida hospitals 3 stories in 22.8 hours
Daily multivitamin slows epigenetic aging in randomized COSMOS analysis 4 stories in 41.8 hours
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity 6 stories in 55.8 hours
White House briefing triggered rapid drops in acetaminophen use in ERs 2 stories in 59.8 hours
MUSC Health buys large South Carolina multispecialty practice for $111M 4 stories in 59.8 hours
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage 19 stories in 84.9 hours
Analysis finds small patient group drives majority of admissions and costs 3 stories in 84.9 hours
Springing forward worsens sleep and sparks health complaints 8 stories in 88.9 hours
Cancer Grand Challenges awards five teams bold funding for cancer research 67 stories in 95.9 hours
Belzutifan combinations highlighted at ASCO GU improve RCC outcomes 3 stories in 97.9 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: